We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
XenoPort announced results from a Phase IIb clinical trial demonstrating that its most advanced product candidate, known as XP13512, provided statistically significant and clinically relevant benefits to patients with Restless Legs Syndrome (RLS) when dosed at 1200 mg once per day for 14 days.
CollaGenex announced that results from a Phase II clinical trial evaluating COL-3 as a treatment for rosacea were presented recently at the summer meeting of the North Carolina Dermatology Association.
Oxford BioMedica has reported that the first stage of its Phase II trial in pancreatic cancer with MetXia, a gene targeted prodrug activation product, has been successfully completed.
Eli Lilly announced that it has completed a Phase III clinical trial in which its investigational drug, ruboxistaurin mesylate (proposed brand name Arxxant) reduced the occurrence of vision loss in patients with diabetic retinopathy (DR).
IVAX announced that its U.S. generic subsidiary, IVAX Pharmaceuticals, will distribute morphine sulfate controlled-release tablets C-II in 15, 30, 60, 100 and 200 mg dosage strengths supplied by Purdue Pharma of Stamford, Conn. Morphine sulfate controlled-release tablets C-II are the generic equivalent of MS Contin
(morphine sulfate controlled-release) Tablets, a narcotic analgesic indicated for the relief of moderate-to-severe pain in patients who require repeated dosing over periods of more than a few days.
A smart anticancer bomb can penetrate deep into tumors where it explodes and destroys cancerous cells without harming healthy ones, researchers at the Massachusetts Institute of Technology announced recently.
The Quigley Corporation has announced that its wholly-owned Quigley Pharma (Ethical Pharmaceuticals) subsidiary has obtained results from its continued preclinical research on QR440, botanical broad-spectrum anti-inflammatory compound, which show that QR440 may have disease-modifying potential.
Axonyx announced that the FDA has approved its investigational new drug (IND) application, submitted in June 2005, allowing Phase I clinical testing of Posiphen.
Paratek Pharmaceuticals announced that it is conducting a Phase I clinical trial of its lead compound from a new class of antibiotics called aminomethylcyclines (AMCs), derived from the well-known tetracycline family.
Cara Therapeutics has reported results of a Phase I clinical trial for its peripherally acting kappa opioid agonist, CR665, which is being developed for the treatment of postoperative pain.